Negative Catalysts Weigh on Nova Nordisk

27 days ago

Bloomberg reporter Chloe Malay

"Nova Nordisk. Stock down facing a negative impulse. Why? Well, it was downgraded to an underweight rating by Morgan Stanley this morning. And so that was driving the stock down. ... weak prescription growth for GRP1s going forward and also growing competition in that space. ... low probability of success for the Evoque trial."

Morgan Stanley downgraded Nova Nordisk to an underweight rating due to weak prescription growth expectations, growing competition, and low probability of success in the Evoque trial for Alzheimer’s. Additional headwinds from past management changes and tariff pressures have compounded the negative sentiment.

Related Stocks